Recently published scientific studies include research into whether Covid-19 immunity might not be possible.
Merck’s Keytruda Approved for First-Line Treatment of Colorectal Cancer
Approvals, Blockbusters, Checkpoint Inhibitors, Clinical Data, FDA, FDA/Regulatory, Microsatellite instability-high (MSI-H) cancer, Microsatellite Instability-High (MSI-H) Colorectal Cancer, Mismatch Repair Deficient (dMMR) Colorectal Cancer, Monotherapy, New Indications, PD-1/PD-L1 inhibitors, Progression-Free Survival (PFS), TherapeuticsThe U.S. Food and Drug Administration approved Merck’s anti-PD-1 therapy Keytruda as monotherapy for the first-line treatment of patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer.
AstraZeneca and Daiichi Sankyo’s Enhertu helped patients with three different types of cancer live longer in trials, pointing to potential broader use of the breast cancer treatment.
Merck’s Keytruda Hits Coprimary Endpoint Early in Colorectal Cancer Trial
Blockbusters, Checkpoint Inhibitors, Chemotherapy, Clinical Trials, Colorectal Cancer, Data Monitoring Committee (DMC), Metastatic Colorectal Cancer (mCRC), Overall Survival (OS), Primary Endpoints, Progression-Free Survival (PFS), R&D, TherapeuticsMerck’s checkpoint inhibitor Keytruda (pembrolizumab) hit one of the coprimary endpoints early in the Phase III KEYNOTE-177 clinical trial for a highly mutating form of colorectal cancer.
Cancer deaths in the United States fell 2.2% from 2016 to 2017 – the largest single-year drop ever recorded – fueled in large part by progress against lung cancer, the leading cause of cancer death, the American Cancer Society (ACS) reported.
Arcus Biosciences and Roche company Genentech are partnering on two clinical trials for colorectal and pancreatic cancer.
Amgen drug shrinks lung cancer tumors in half of patients: study
Advanced lung cancer, Cancer Cells, Cancer Deaths, Checkpoint Inhibitors, Chemotherapy, Clinical Data, Clinical Trials, Colorectal Cancer, Genetic Mutations, Immune System, KRAS Mutations, Non-Small Cell Lung Cancer, R&D, Tumor Shrinkage, Wall Street, World Conference on Lung CancerAn experimental Amgen Inc. drug that targets a specific genetic mutation reduced tumor size in around half of advanced lung cancer patients given the highest dose in a small, early-stage trial.
Freenome snagged $160 million in Series B financing to support the development of the company’s early cancer detection blood test.
Bayer, Bristol-Myers Squibb and Ono Pharmaceutical teamed up to study the most common type of metastatic colorectal cancer.